In this section
Next Generation Sequencing (NGS) technology allows the simultaneous analysis of multiple genes.
A pan-myeloid NGS panel is available for all new or potential diagnoses of AML; broad panel testing is also funded for MDS, MDS/MPN overlap and MPN. A virtual panel of JAK2 (including exon 12), CALR and MPL will be applied to all suspected referrals of MPN in place of single gene testing with information on additional genes available on request.
Gene fusion testing by RNAseq is also available on request. This assay is designed to detect all relevant fusions that act via the generation of a chimeric RNA transcript.
More information on myeloid panel genes and their use in clinical management can be found here.